Tag: <span>drosophila s2</span>

Spinning Out: From Concept to Actualization

ExpreS2ion, established in January 2010, is located in the Hørsholm Science Park, north of Copenhagen. It was formed as a spin-out from Affitech A/S (Affitech) which holds an equity position in the company. ExpreS2ion operates as a contract research organization (CRO) offering services related to vector and cell line development, cloning, upstream development, optimization, and production of GLP material using its S2 (Drosophila Schneider 2) cell-based ExpreS2 platform. Two of the company’s founders, Drs. de Jongh and Dyring, and early employees of ExpreS2ion were colleagues for many years at Affitech and Pharmexa A/S (Pharmexa) before the two companies combined. It was during this period that they developed and optimized a S2 expression system for use in the production of therapeutic vaccines. ExpreS2ion’s proprietary protein expression platform, ExpreS2, consists of high-yielding expression vectors, a S2 cell line that grows to higher cell densities than standard S2 cells, an optimized culture media, and a highly efficient transfection reagent specifically optimized for S2 cells…

Read MoreSpinning Out: From Concept to Actualization

Biologics Production

cell line development drosophila s2 drosophila schneider 2 glp material life sciences protein expression therapeutic vaccines therapeutics vaccine production vectors

Optimising the Drosophila S2 Expression System for Production of Therapeutic Vaccines

Continuous cell lines of Drosophila have now been in use for more than two decades as hosts for the expression of heterologous gene products. The most popular are the Schneider lines 2 and 3 (S2, S3) and a few derivatives of the Kc line. These have been widely employed for both stable and transient gene expression. The S2, in particular, is an exceptionally versatile system that has proven to be useful for high-level protein production. S2 cells have been used for the expression and analysis of intracellular, secreted, and membrane-associated proteins. This includes cytokines, antibodies, receptors, and viral antigens. These have all been shown to be authentically-processed, biologically active, and produced to high levels. The cell line is ideally suited for the development and industrial-scale manufacturing of a wide range of biopharmaceuticals including vaccines and therapeutic protein products. Compared to conventional technologies, the strengths of the S2 expression technology lie in its quick access to proteins, excellent protein expression capability, scalability, regulatory-friendliness, and applicability to high cell density perfusion cultivation…

Read MoreOptimising the Drosophila S2 Expression System for Production of Therapeutic Vaccines

Biologics Production

biopharmaceutical manufacturing cytokines drosophila s2 heterologous gene products intracellular proteins membrane-associated proteins s2 expression system schneider s2 therapeutic vaccines